News | Image Guided Radiation Therapy (IGRT) | March 30, 2016

Adaptive Image-guided Radiotherapy Effective in Bladder Cancer

Study sees increased bladder preservation rates over surgery with good oncological outcomes

March 30, 2016 — A prospective study examining a trimodality treatment approach in localized bladder cancer cases using adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT) found the bladder preservation rate at three years was 83 percent.

Approximately 150,000 people worldwide die every year as a result of urinary bladder cancer. Patients with moderately advanced bladder cancer typically undergo surgery with removal of the bladder resulting in the use of an external urine bag. The trimodality plan, which consists of the transurethral resection of the bladder tumor (TURBT), IG-IMRT and chemotherapy, was developed as a bladder conservation protocol to preserve bladder function with good oncological outcomes.  

“Adaptive IGRT [with] plan-of-the-day approach for bladder preservation is clinically feasible, with good oncological outcomes and low rates of acute and late toxicities. Dose escalation is safe and possibly improves outcomes in bladder preservation,” said Vedang Murthy, M.D., radiation oncology, Tata Memorial Centre, Mumbai, India, and lead author of the study.

The study, “Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study,” was published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).

“With adaptive IGRT, increasing the dose becomes possible, and serious side effects may be kept low, ensuring a good quality of life for our patients,” Murthy said.

The study looked at 44 patients between August 2008 and August 2014. Thirty-nine (88 percent) patients were male and five (11 percent) were female, ranging in ages from 55 to 72. Eighty-eight percent of patients had stage 2 disease. Patients underwent maximal safe resection of bladder tumor and concurrent platinum-based chemotherapy, and those with large tumors were offered induction chemotherapy.

RT planning was done using either three (n=34) or six (n=10) non-concentrically grown planning target volumes (PTV). Patients received 64 Gy in 32 fractions to the whole bladder and 55 Gy to the pelvic nodes. If appropriate, they received a simultaneous integrated boost to the tumor bed to 68 Gy. Daily megavoltage imaging was used to find the most appropriate PTV encompassing bladder for the particular day with the plan-of-the-day approach.

At six to ten weeks post-treatment, all patients had a complete response. The study had a median follow-up of 30 months. Overall survival at the last follow-up was 77 percent (34 patients). Among those who died, three died from comorbidities and were disease-free at the time of death.

The three-year locoregional control (LRC), disease-free survival and overall survival (OS) rates were 78 percent, 66 percent and 67 percent, respectively. Rates of LRC and OS were better in patients who received dose escalation. Acute and late Radiation Therapy Oncology Group (RTOG) grade 3 genitourinary toxicity was seen in five (11 percent) and two (four percent) patients, respectively. No acute or late RTOG grade 3 or higher gastrointestinal toxicity occurred.

“Adaptive RT (ART) further helps in reduction of doses to normal tissues and improves accuracy of delivery,” Murthy said. “These procedures, in theory, should result in less acute and late toxicity, while allowing for dose escalation to gross tumor to improve outcomes.”

“Although a number of investigators have conceived and developed a variety of ART techniques, there are few clinical outcome data to validate this dosimetric concept. The present proof-of-concept prospective study was conducted with the aim of establishing the safety, efficacy and feasibility of IG-IMRT-based ART in clinical practice,” he said.

More follow-up with larger groups of patients is needed to establish the novel technique as the standard, Murthy said, but results from the study have shown the possibilities of ART in bladder cancer patients.

“These results provide proof of concept of using adaptive IGRT in the clinic,” Murthy said. “This will hopefully lead to more and more suitable patients undergoing bladder preservation around the world.”

For more information: www.redjournal.org

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...